Page 274 - ebook HCC

PROGRAMME AND ABSTRACTSAND ABSTRACTS
EASL
GENEV
272
272 PROGRAMME GENEVA, SWITZERLANDA, SWITZERLAND EASL HCC SUMMITHCC SUMMIT 273
273
FEBRUARY 13 - 16, 2014Y 13 - 16, 2014
FEBRUAR
Poster Board Number C49
CHUBBY IS BEATIFUL: SUBCUTANEOUS FAT Tab.1 Total population (n=58) 95% LCL-UCL
AREA AS PREDICTOR OF BETTER SURVIVAL Male (n%) 48 (83%)
IN PATIENTS WITH HCC TREATED WITH Age (mean±ds) 68.3±9.8 65.7-70.8
SFA (mm ) (mean±ds)
13,382.1-18,995.2
16,188 ± 10,673
2
SORAFENIB VFA (mm ) (mean±ds) 12,618.8 + 6,829.5 10,823.1-14,415.5
2
Cirrhosis (n) % 54 (93%)
CP score (mean±ds) 5.9±1 5.6-6.2
Adriano De Santis , Claudia Iegri , Giulia Gallusi , Michele Di Martino , Meld score (mean±ds) 7.6±3.3 6.7-8.6
1
1 2
1
1
Chiara Bassanelli , Mariana Forlino , Carmen D. Ciesco BCLC(n)(%)
1 2
1 2
2
1 Gastronterology Division, Clinical Medicine Department, Radiology Department, B /C
Policlinico Umberto 1, Rome, Italy 25 (42%)33 (58%)
ECOG (n)(%)
0/1
Corresponding author’s e-mail: claudia.iegri@gmail.com 43 (74%)15 (26%)
Introduction: A potential relationship between body fat content and response to Sorafenib Tab.2 SFA VFA
treatment has been suggested for renal cell carcinoma but not in HCC. > median ≤ median p > median ≤ median p
(29 pts) (29pts) (29pts) (29pts)
Aims: Sorafenib is a highly lipophilic molecule. So, we supposed that in well nourished CP score (mean±ds) 5.8±1.04 6.2±1.01 ns 6±1.07 6±1.04 ns
pts, Sorafenib could be stored and then steadily released thus maintaining long-term Meld score (mean±ds) 7.7±3.5 7.6±3.4 ns 7.9±3.4 7.4±3.4 ns
higher plasma levels than in underweight pts. Our aim was to evaluate a potential BCLC C (n%) 15 (52%) 18 (62%) ns 15 (52%) 18 (62%) ns
relationship between subcutaneous (SFA) and visceral fat area (VFA), and survival in pts ECOG 0 (n%) 24(82%) 19 (66%) ns 22 (76%) 21 (72%) ns
with advanced HCC treated with Sorafenib.
Conclusion: Our study suggest a role of SFA as a predictor of better survival in pts treated
Methodology: SFA and VFA were retrospectively measured at the level of the umbilicus, as with Sorafenib.So,the maintenance of nutritional status during Sorafenib treatment seems
previously described [1],on baseline CT scan of 58 pts with HCC candidates to Sorafenib. to be an important goal.
Results: The baseline clinical-anthropometric characteristics of pts are summarized in
CLINICAL POSTER ABSTRACTS mm – SFA- and ≤ or > 11534 mm VFA).Clinical characteristics of pts stratified according CLINICAL POSTER ABSTRACTS
table 1.Given the absence of reference interval of SFA and VFA in literature, the values
were dichotomized using the median of observed distribution as the cut-off (≤ or > 14061

2-
2
SFA and VFA value are showed in table 2. Time to progression (TTP) was longer in pts
with higher SFA and VFA although not significantly. In pts with higher SFA mean survival
was significantly longer (319.3 ± 244.4 days vs 194.3 ± 224.4 d; p=0.04). Also in pts with
higher VFA the mean survival was longer but not significantly. At multivariate analysis SFA
was confirmed as the only independent predictive factors of better survival (Regression
coefficient: - 0.000059; CI: - 0.000118-0; RR: 0.99; p = 0.04). The Kaplan Meyer analysis
for survival stratified according SFA is reported in Figure 1.